

Quanterix

Kevin Hrusovsky Joins Quanterix as Executive Chairman

Lexington, Mass. – June 10, 2014 - [Quanterix Corporation](#), a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Kevin Hrusovsky as Executive Chairman of its Board of Directors.

Hrusovsky brings over twenty years of experience in life science and diagnostics industries with a strong track record for building substantial value commercializing disruptive technologies. Prior to Quanterix, he was President of PerkinElmer Life Sciences & Technology; CEO of Caliper Life Sciences (sold to Perkin Elmer); and CEO of Zymark (sold to Caliper). Earlier Hrusovsky was President of FMC Corporation's Pharmaceuticals and International Agricultural Products and held management positions at E.I. DuPont de Nemours. He serves on the Board of Director's of SynapDx, 908 Devices and Solect Energy.

Hrusovsky received his B.S. in Mechanical Engineering from the Ohio State University (OSU) and M.B.A. from Ohio University. He was awarded OSU's 2013 Entrepreneur of the Year and an Honorary Doctorate degree from Framingham State University for contributions to life sciences and personalized medicine.

"I am compelled by the far reaching potential of Quanterix' Simoa technology, the caliber of its people and Board of Directors and by the impressive opportunity to impact the world," said Hrusovsky, "Quanterix is poised to enable a whole new field of science and exploration, i.e., unprecedented ability to precisely detect ultra-low levels of proteins in humans and other forms of life."

The appointment comes as Martin Madaus, formerly the Executive Chairman of the Board at Quanterix, is appointed Chairman and CEO of Ortho-Clinical Diagnostics (OCD) following the close of its acquisition from Johnson & Johnson by the Carlyle Group. Madaus will remain a member of Quanterix' Board of Directors. "I couldn't be more pleased that Kevin has accepted to become our new Executive Chairman at Quanterix," said Madaus, "He is an outstanding leader with a strong track record for guiding innovative companies and creating value for shareholders and a great fit for Quanterix. Since the launch of the first Simoa products last year, the company has experienced rapid growth. Kevin's leadership and experience will ensure the team at Quanterix has the support needed to continue that trajectory."

To learn more about Simoa, please visit: www.quanterix.com.

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com

###

Contacts:

Nikki Festa/Caitlyn Keating

PAN Communications

617-502-4300

quanterix@pancomm.com

¹ Leporet. *al.*, *British Journal of Urology*, October 2011

² Song *et. al.*, *Journal of Immunological Methods*, September 2011

³ Zetterberg *et. al.*, *PLoS ONE*, December 2011